FRAXA Drug Validation Initiative (FRAXA-DVI)

The FRAXA Drug Validation Initiative (FRAXA-DVI) provides speedy, cost-effective, objective preclinical testing to validate investigational and repurposed compounds for Fragile X.

Read More »

Finding Fragile X Biomarkers – From Transcriptomics to Behavior in Patients

FRAXA funded a study using blood-based transcriptomics to find reliable Fragile X biomarkers. This unique approach links molecular data to behavior for future trials.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)